检索结果-南通市图书馆

Research in Astronomy and Astrophysics 2014年第12期14卷 1633-1641页

作者： Hong-Bo zhang lei Zheng Yan Su Guang-You Fang Bin Zhou jian-Qing feng Shu-Guo Xing Shun Dai Jun-Duo li Yi-Cai ji yun-Ze Gao Yuan Xiao Chun-Lai li Key Laboratory of Lunar and Deep Space Exploration National Astronomical ObservatoriesChinese Academy of Sciences Institute of Electronics Chinese Academy of Sciences

Lunar Penetrating Radar （LPR） onboard the rover that is part of the Chang＇e-3 （CE-3） mission was firstly utilized to obtain in situ measurements about geological structure on the lunar surface and the thickness of the lunar regolith, which are key elements for studying the evolutional history of lunar crust. Because penetra- tion depth and resolution of LPR are related to the scientific objectives of this mission, a series of ground-based experiments using LPR was carried out, and results of the experimental data were obtained in a glacial area located in the northwest region of China. The results show that the penetration depth of the first channel antenna used for LPR is over 79 m with a resolution of 2.8 m, and that for the second channel antenna is over 50.8 m with a resolution of 17.1 cm.

关键词： Moon -- techniques: radar astronomy -- methods: analytical

Progress in ceramic materials and structure design toward advanced thermal barrier coatings

在线全文

学校读者我要写书评

暂无评论

Journal of Advanced Ceramics 2022年第7期11卷 985-1068页

作者： Zhi-Yuan WEI Guo-Hui MENG lin CHEN Guang-Rong li Mei-Jun liU Wei-Xu zhang li-Na ZHAO Qiang zhang Xiao-Dong zhang Chun-lei WAN Zhi-Xue qu lin CHEN jing feng ling liU Hui DONG Ze-Bin BAO Xiao-feng ZHAO Xiao-feng zhang lei GUO liang WANG Bo CHENG Wei-Wei zhang Peng-yun XU Guan-Jun YANG Hong-Neng CAI Hong CUI You WANG Fu-Xing YE Zhuang MA Wei PAN Min liU Ke-Song ZHOU Chang-jiu li State Key Laboratory for Mechanical Behavior of Materials School of Materials Science and EngineeringXi’an Jiaotong UniversityXi’an 710049China State Key Laboratory for Strength and Vibration of Mechanical Structures Department of Engineering MechanicsSchool of Aerospace EngineeringXi’an Jiaotong UniversityXi’an 710049China Xi’an Aerospace Composite Research Institute Xi’an 710025China AECC Beijing Institute of Aeronautical Materials Beijing 100095China School of Materials Science and Engineering Harbin Institute of TechnologyHarbin 150001China State Key Laboratory of New Ceramics&Fine Processing School of Materials Science and EngineeringTsinghua UniversityBeijing 100084China Faculty of Materials and Manufacturing Key Laboratory of Advanced Functional MaterialsEducation Ministry of ChinaFaculty of Materials and ManufacturingBeijing University of TechnologyBeijing 100124China Faculty of Materials Science and Engineering Kunming University of Science and TechnologyKunming 650093China School of Materials Science and Engineering Beijing Institute of TechnologyBeijing 100081China Xi’an Key Laboratory of High Performance Oil and Gas Field Materials School of Materials Science and EngineeringXi’an Shiyou UniversityXi’an 710065China Shi-Changxu Innovation Center for Advanced Materials Institute of Metal ResearchChinese Academy of SciencesShenyang 110016China Shanghai Key Laboratory of Advanced High-temperature Materials and Precision Forming Shanghai Jiao Tong UniversityShanghai 200240China National Engineering Laboratory for Modern Materials Surface Engineering Technology the Key Lab of Guangdong for Modern Surface Engineering TechnologyInstitute of New MaterialsGuangdong Academy of SciencesGuangzhou 510650China School of Materials Science and Engineering Tianjin UniversityTianjin 300072China Integrated Computational Materials Research Centre Shanghai Institute of CeramicsChinese Academy of SciencesShanghai 201899China State Key Laboratory of Advanced Processing and Recycling of

Thermal barrier coatings(TBCs)can effectively protect the alloy substrate of hot components in aeroengines or land-based gas turbines by the thermal insulation and corrosion/erosion resistance of the ceramic top ***,the continuous pursuit of a higher operating temperature leads to degradation,delamination,and premature failure of the top *** new ceramic materials and new coating structures must be developed to meet the demand for future advanced TBC *** this paper,the latest progress of some new ceramic materials is first ***,a comprehensive spalling mechanism of the ceramic top coat is summarized to understand the dependence of lifetime on various factors such as oxidation scale growth,ceramic sintering,erosion,and calcium–magnesium–aluminium–silicate(CMAS)molten salt ***,new structural design methods for high-performance TBCs are discussed from the perspectives of lamellar,columnar,and nanostructure *** latest developments of ceramic top coat will be presented in terms of material selection,structural design,and failure mechanism,and the comprehensive guidance will be provided for the development of next-generation advanced TBCs with higher temperature resistance,better thermal insulation,and longer lifetime.

关键词： thermal barrier coatings(TBCs) ceramic material degradation and failure structure design long lifetime

Interaction of H2+ molecular beam with thin layer graphene foils

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Physics B 2019年第9期28卷 164-168页

作者： Min li Guo-feng qu Yi-Zhou Wang Zhou-Sen Zhu Mian-Gong Shi Mao-lei Zhou Dong liu Zi-Xu Xu Ming-jiang Song Jun zhang Fan Bai Xiao-Dong liao ji-feng Han Key Laboratory of Radiation Physics and Technology of the Ministry of Education Institute of Nuclear Science and TechnologySichuan UniversityChengdu 610064China College of Physics and Electronic Engineering Sichuan Normal UniversityChengdu 610066China

The interaction of MeV H2^+ molecular ions with thin layer graphene and graphite foils was studied by using a highresolution electrostatic analyzer.A large number of fragment protons were observed at zero degree(along the beam direction) when the H2^+ beam was passing through the monolayer graphene foil, which indicates that the electron of the H2^+ molecular ions can be stripped easily even by the monolayer graphene *** trailing than leading protons were found in the energy spectrum, which means significant wake effect was observed in the monolayer graphene *** ratio of the numbers of trailing protons over leading protons first increased with the thickness for the much thinner graphene foils, and then decreased with the thickness for the much thicker graphite foils, which indicates that the bending effect of the wake field on the trailing proton varied with the foil thickness.

关键词： H2^+ molecular ions graphene electron stripping wake effect

Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV:a phase 2 trial

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2022年第7期7卷 2522-2532页

作者： Nawal Al Kaabi yun Kai Yang jing zhang Ke Xu Yu liang yun Kang ji Guo Su Tian Yang Salah Hussein Mohamed Saif ElDein Shuai Shao Sen Sen Yang Wenwen lei Xue Jun Gao Zhiwei jiang Hui Wang Meng li Hanadi Mekki Mekki Walid Zaher Sally Mahmoud Xue zhang Chang qu Dan Ying liu jing zhang Mengjie Yang Islam Eltantawy Peng Xiao Zhao Nian Wang jin liang Yin Xiao Yan Mao jin zhang Ning liu Fu jie Shen liang qu yun Tao zhang Xiao Ming Yang Guizhen Wu Qi Ming li Sheikh Khalifa Medical City SEHAAbu DhabiUnited Arab Emirates College of Medicine and Health Sciences Khalifa UniversityAbu DhabiUnited Arab Emirates China National Biotec Group Company limited BeijingChina The Sixth Laboratory National Vaccine and Serum Institute(NVSI)BeijingChina National Engineering Center for New Vaccine Research BeijingChina National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and Prevention(China CDC)BeijingChina Lanzhou Institute of Biological Products Company limited LanzhouChina Beijing Key Tech Statistical Consulting Co. LtdBeijingChina Beijing Institute of Biological Products Company limited BeijingChina Union 71 Abu DhabiUnited Arab Emirates G42 Healthcare Abu DhabiUnited Arab Emirates

The increased coronavirus disease 2019(COVID-19)breakthrough cases pose the need of booster *** conducted a randomised,double-blinded,controlled,phase 2 trial to assess the immunogenicity and safety of the heterologous prime-boost vaccination with an inactivated COVID-19 vaccine(BBIBP-CorV)followed by a recombinant protein-based vaccine(NVSI-06-07),using homologous boost with BBIBP-CorV as *** groups of healthy adults(600 individuals per group)who had completed two-dose BBIBP-CorV vaccinations 1–3 months,4–6 months and≥6 months earlier,respectively,were randomly assigned in a 1:1 ratio to receive either NVSI-06-07 or BBIBP-CorV *** assays showed that in NVSI-06-07 groups,neutralizing antibody geometric mean titers(GMTs)against the prototype SARS-CoV-2 increased by 21.01–63.85 folds on day 28 after vaccination,whereas only 4.20–16.78 folds of increases were observed in control *** Omicron variant,the neutralizing antibody GMT elicited by homologous boost was 37.91 on day 14,however,a significantly higher neutralizing GMT of 292.53 was induced by heterologous *** results were obtained for other SARS-CoV-2 variants of concerns(VOCs),including Alpha,Beta and *** heterologous and homologous boosters have a good safety *** and systemic adverse reactions were absent,mild or moderate in most participants,and the overall safety was quite similar between two booster *** findings indicated that NVSI-06-07 is safe and immunogenic as a heterologous booster in BBIBP-CorV recipients and was immunogenically superior to the homologous booster against not only SARS-CoV-2 prototype strain but also VOCs,including Omicron.

关键词： phase neutral GMT

Petrology and metamorphism of glaucophane eclogites in Changning-Menglian suture zone, Bangbing area, southeast Tibetan Plateau: An evidence for Paleo-Tethyan subduction

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

China Geology 2021年第1期4卷 111-125页

作者： Yu-zhen Fu Zhi-ming Peng Bao-di Wang Guo-zhi Wang jing-feng Hu Jun-lei Guan ji zhang zhang zhang yun-he liu Zou Hao College of Earth Sciences Chengdu University of TechnologyChengdu 610059China Key Laboratory of Tectonic Controls on Mineralization and Hydrocarbon Accumulation of Ministry of Natural Resources Chengdu University of TechnologyChengdu 610059China Chengdu Center of China Geological Survey Ministry of Natural ResourcesChengdu 610081China Institute No.280 of China National Nuclear Corporation Guanghan 618300China

High/ultrahigh-pressure(HP/UHP)metamorphic complexes,such as eclogite and blueschist,are generally regarded as significant signature of paleo-subduction zones and paleo-suture *** eclogites have been recently identified within the Lancang Group characterized by accretionary mélange in the Changning-Menglian suture zone,at Bangbing in the Shuangjiang area of southeastern Tibetan *** authors report the result of petrological,mineralogical and metamorphism investigations of these rocks,and discuss their tectonic *** eclogites are located within the Suyi blueschist belt and occur as tectonic lenses in coarse-grained garnet muscovite *** major mineral assemblage of the eclogites includes garnet,omphacite,glaucophane,phengite,clinozoisite and *** garnet contains numerous inclusions,such as omphacite,glaucophane,rutile,and quartz with radial cracks *** and clinozoisite in the matrix have apparent optical and compositional *** stages of metamorphic evolution can be determined:The prograde blueschist facies(M_(1)),the peak eclogite facies(M_(2)),the decompression blueschist facies(M_(3))and retrograde greenschist facies(M_(4)).Using the Grt-Omp-Phn geothermobarometer,a peak eclogite facies metamorphic P-T condition of 3000–3270 MPa and 617–658℃ was determined,which is typical of low-temperature ultrahigh-pressure *** comparison of the geological characteristics of the Bangbing glaucophane eclogites and the Mengku lawsonite-bearing retrograde eclogites indicates that two suites of eclogites may have formed from significantly different depths or localities to create the tectonic mélange in a subduction channel during subduction of the Triassic Changning-Menglian *** discovery of the Bangbing glaucophane eclogites may represent a new oceanic HP/UHP metamorphic belt in the Changning-Menglian suture zone.

关键词： Eclogite HP/UHP metamorphism Subduction channel Changning-Menglian suture zone Paleo-Tethyan subduction Geological survey engineering Southeast Tibetan Plateau

FOXO3-engineered human mesenchymal progenitor cells efficiently promote cardiac repair after myocardial infarction

在线全文

学校读者我要写书评

暂无评论

Protein & Cell 2021年第2期12卷 145-151页

作者： jinghui lei Si Wang Wang Kang qun Chu Zunpeng liu liang Sun yun ji Concepcion Rodriguez Esteban Yan Yao Juan Carlos Izpisua Belmonte Piu Chan Guang-Hui liu Weiqi zhang Moshi Song jing qu Advanced Innovation Center for Human Brain Protection National Clinical Research Center for Geriatric DisordersXuanwu Hospital Capital Medical UniversityBeijing 100053China State Key Laboratory of Membrane Biology Institute of ZoologyChinese Academy of SciencesBeijing 100101China State Key Laboratory of Stem Cell and Reproductive Biology Institute of ZoologyChinese Academy of SciencesBeijing 100101China Disease Genomics and Individualized Medicine Laboratory Beijing Institute of GenomicsChinese Academy of SciencesBeijing 100101China Institute of Stem Cell and Regeneration Chinese Academy of SciencesBeijing 100101China University of Chinese Academy of Sciences Beijing 100049China The MOH Key Laboratory of Geriatrics Beijing HospitalNational Center of GerontologyBeijing 100730China Department of Cardiology Beijing Anzhen HospitalCapital Medical UniversityBeijing 100029China Gene Expression Laboratory Salk Institute for Biological StudiesLa Jolla 92037USA

Dear Editor,Myocardial infarction(MI)is the irreversible cardiomyocyte death resulting from prolonged oxygen deprivation due to obstructed blood supply(ischemia),leading to contractile dysfunction and cardiac *** recent decades,stem cell transplantation has been extensively investigated for the repair of injured heart in animal studies and clinical trials(Kanelidis et al.,2017;Gyongyosi et al.,2018).

关键词： al. infarction cardiac

XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer:An open-labeled,multicenter,randomized,prospective phase III trial(EXELOX)

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2022年第4期42卷 314-326页

作者： Xiao-Dong Zhu Ming-Zhu Huang Yu-sheng Wang Wan-jing feng Zhi-Yu Chen Yi-Fu He Xiao-Wei zhang Xin liu Chen-Chen Wang Wen zhang jie-Er Ying Jun Wu lei Yang Yan-Ru Qin jian-feng Luo Xiao-Ying Zhao Wen-Hua li Zhe zhang li-Xin Qiu Qi-Rong Geng jian-ling Zou jie-yun zhang Hong Zheng Xue-feng Song Shu-sheng Wu Cheng-Yan zhang Zhe Gong Qin-Qin liu Xiao-feng Wang Qi Xu Qi Wang jian-Mei ji jian Zhao Wei-jian Guo Department of Gastrointestinal Medical Oncology Fudan University Shanghai Cancer CenterShanghai 200032P.R.China Department of Oncology Shanghai Medical CollegeFudan UniversityShanghai 200032P.R.China Department of Gastroenterology Shanxi Cancer HospitalTaiyuanShanxi 030013P.R.China Department of Medical Oncology The First Affiliated HospitalDivision of Life Science and MedicineUniversity of Science and Technology of ChinaHefeiAnhui 230031P.R.China Department of Abdominal Medical Oncology Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital)Institute of Cancer and Basic Medicine(IBMC)Chinese Academy of SciencesHangzhouZhejiang 310005P.R.China Department of Medical Oncology The First People’s Hospital of ChangzhouChangzhouJiangsu 213004P.R.China Department of Gastroenterology Nantong Tumor HospitalNantongJiangsu 226006P.R.China Department of Oncology Zhengzhou University First Affiliated HospitalZhengzhouHenan 450052P.R.China Department of Biostatistics School of Public HealthFudan UniversityShanghai 200032P.R.China Department of medical oncology Cancer Hospital of Fudan UniversityMinhang BranchShanghai 200032P.R.China

Background:There is no consensus on whether triplet regimen is better than doublet regimen in the first-line treatment of advanced gastric cancer(AGC).We aimed to compare the efficacy and safety of oxaliplatin plus capecitabine(XELOX)and epirubicin,oxaliplatin,plus capecitabine(EOX)regimens in treating ***:This phase III trial enrolled previously untreated patients with AGC whowere randomly assigned to receive the XELOXor *** primary endpoint was non-inferiority in progression-free survival(PFS)for XELOX as compared with EOX on an intention-to-treat ***:Between April 10,2015 andAugust 20,2020,448AGCpatientswere randomized to receive XELOX(n=222)or EOX(n=226).The median PFS(mPFS)was 5.0 months(95%confidence interval[CI]=4.5-6.0 months)in the XELOX arm and 5.5 months(95%CI=5.0-6.0 months)in the EOX arm(hazard ratio[HR]=0.989,95%CI=0.812-1.203;P_(non-inferiority)=0.003).There was no significant difference inmedian overall survival(mOS)(12.0 vs.12.0months,P=0.384)or objective response rate(37.4%vs.45.1%,P=0.291)between the two *** patients with poorly differentiated adenocarcinoma and liver metastasis,the EOX arm had a significantly longer mOS(P=0.021)and a trend of longer mPFS(P=0.073)than the XELOX *** rate of grade 3/4 adverse events(AEs)was 42.2%(90/213)in the XELOX arm and 72.5%(156/215)in the EOX arm(P=0.001).The global health-related quality of life(QoL)score was significantly higher in the XELOX arm than in the EOX arm during ***:This non-inferiority trial demonstrated that the doublet regimen was as effective as the triplet regimen and had a better safety profile and QoL as a first-line treatment for AGC ***,the triplet regimen might have a survival advantage in patients with poorly differentiated adenocarcinoma and liver metastasis.

关键词： Advanced gastric cancer chemotherapy XELOX doublet regimen EOX triplet regimen noninferiority quality of life phase III trial

The Chinese Society of Clinical Oncology(CSCO):Clinical guidelines for the diagnosis and treatment of gastric cancer,2021

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2021年第8期41卷 747-795页

作者： feng-Hua Wang Xiao-Tian zhang Yuan-Fang li lei Tang Xiu-Juan qu jie-Er Ying Jun zhang ling-Yu Sun Rong-Bo lin Hong Qiu Chang Wang Miao-Zhen Qiu Mu-Yan Cai QiWu Hao liu Wen-Long Guan Ai-Ping Zhou Yu-jing zhang Tian-Shu liu feng Bi Xiang-lin Yuan sheng-Xiang Rao Yan Xin Wei-Qi sheng Hui-Mian Xu Guo-Xin li jia-Fu ji Zhi-Wei Zhou Han liang Yan-Qiao zhang jing jin lin Shen jin li Rui-Hua Xu Department of Medical Oncology State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142P.R.China Department of Gastric Surgery State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Radiology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142P.R.China Department of Medical Oncology The First Hospital of China Medical UniversityShenyangLiaoning 110001P.R.China Department of Medical Oncology Zhejiang Cancer HospitalHangzhouZhejiang 310006P.R.China Department of Medical Oncology Ruijin HospitalShanghai Jiaotong University School of MedicineShanghai 200025P.R.China Department of Surgical Oncology The Fourth Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiang 150001P.R.China Department of Medical Oncology Fujian Cancer HospitalFuzhouFujian 350000P.R.China Department of Medical Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubei 430030P.R.China Cancer Center of The First Hospital of jilin University ChangchunJilin 130021P.R.China Department of Pathology State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center of Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Endoscopy Center Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142P.R.China Department of General Surgery Nanfang HospitalSouthern Medical UniversityGuangzhouGuan

There exist differences in the epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selections between gastric cancer patients from the Eastern and Western *** Chinese Society of Clinical Oncology(CSCO)has organized a panel of senior experts specializing in all sub-specialties of gastric cancer to compile a clinical guideline for the diagnosis and treatment of gastric cancer since 2016 and renews it *** into account regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted expert consensus judgment on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes in *** 2021 CSCO Clinical Practice Guidelines for Gastric Cancer covers the diagnosis,treatment,follow-up,and screening of gastric *** on the 2020 version of the CSCO Chinese Gastric Cancer guidelines,this updated guideline integrates the results ofmajor clinical studies from China and overseas for the past year,focused on the inclusion of research data from the Chinese population for more personalized and clinically relevant *** the comprehensive treatment of non-metastatic gastric cancer,attentions were paid to neoadjuvant *** value of perioperative chemotherapy is gradually becoming clearer and its recommendation level has been *** the comprehensive treatment of metastatic gastric cancer,recommendations for immunotherapy were included,and immune checkpoint inhibitors fromthird-line to the first-line of treatment for different patient groups with detailed notes are provided.

关键词： adjuvant chemotherapy Chinese Society of Clinical Oncology(CSCO) diagnosis gastric cancer immunotherapy neoadjuvant radiotherapy surgery targeted therapy

2023:A year of accomplishments for the 13 Science Citation Index Expanded-and Emerging Sources Citation Index-indexed Baishideng journals

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2024年第1期30卷 9-16页

作者： jin-lei Wang jia-Ping Yan jia-Ru Fan Xiang li Xu Guo jia-Wei li yun-Xiaojian Wu jing-jie Wang Yu-Lu Chen li li Cong lin Xin-liang qu ji-Hong liu Yan-liang zhang Ying-Yi Yuan Hua-Ge Yu Yu-Xi Chen Yi-Xuan Cai Xiang-Di zhang Si Zhao Zi-Hang Xu li Ma Na Ma Diao-Mei Guo lian-sheng Ma Baishideng Publishing Group Inc PleasantonCA 94566United States

In 2023,Baishideng Publishing Group(Baishideng)routinely published 47 openaccess journals,including 46 English-language journals and 1 Chinese-language *** successes were accomplished through the collective dedicated efforts of Baishideng staffs,Editorial Board Members,and Peer *** these 47 Baishideng journals,7 are included in the Science Citation Index Expanded(SCIE)and 6 in the Emerging Sources Citation Index(ESCI).With the support of Baishideng authors,company staffs,Editorial Board Members,and Peer Reviewers,the publication work of 2023 is about to be successfully *** editorial summarizes the 2023 activities and accomplishments of the 13 SCIEand ESCI-indexed Baishideng journals,outlines the Baishideng publishing policy changes and additions made this year,and highlights the unique advantages of Baishideng journals.

关键词： Baishideng Publishing Group Journal Impact Factor Open access Policy changes Policy additions Unique advantages Anxiety disorders Colorectal cancer Inflammatory bowel disease Hepatocellular carcinoma Gut microbes Atrial fibrillation

Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants:a randomized phase 2 trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第2期8卷 672-682页

作者： Nawal Al Kaabi yun Kai Yang Yu liang Ke Xu Xue feng zhang yun Kang Yu Qin jin Jun Wei Hou jing zhang Tian Yang Salah Hussein Mohamed Saif ElDein Ze Hua lei Hao zhang Shuai Shao Zhao Ming liu Ning liu Xiang Zheng ji Guo Su Sen Sen Yang Xiangfeng Cong Yao Tan Wenwen lei Xue Jun Gao Zhiwei jiang Hui Wang Meng li Hanadi Mekki Mekki Walid Zaher Sally Mahmoud Xue zhang Chang qu Dan Ying liu jing zhang Mengjie Yang Islam Eltantawy Peng Xiao Fu jie Shen jin Juan Wu Zi Bo Han li Fang Du Fang Tang Shi Chen Zhi jing Ma Fan Zheng Ya Nan Hou Xin Yu li Xin li Zhao Nian Wang jin liang Yin Xiao Yan Mao jin zhang liang qu yun Tao zhang Xiao Ming Yang Guizhen Wu Qi Ming li Sheikh Khalifa Medical City SEHAAbu DhabiUAE College of Medicine and Health Sciences Khalifa UniversityAbu DhabiUAE China National Biotec Group Company limited BeijingChina The Sixth Laboratory National Vaccine and Serum Institute(NVSI)BeijingChina National Engineering Center for New Vaccine Research BeijingChina National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and Prevention(China CDC)BeijingChina Clinical Medicine Office National Vaccine and Serum Institute(NVSI)BeijingChina Lanzhou Institute of Biological Products Company limited LanzhouChina Beijing Key Tech Statistical Consulting Co. LtdBeijingChina Beijing Institute of Biological Products Company limited BeijingChina Union 71 Abu DhabiUAE G42 Healthcare Abu DhabiUAE

An ongoing randomized,double-blind,controlled phase 2 trial was conducted to evaluate the safety and immunogenicity of a mosaic-type recombinant vaccine candidate,named NVSI-06-09,as a booster dose in subjects aged 18 years and older from the United Arab Emirates(UAE),who had administered two or three doses of inactivated vaccine BBIBP-CorV at least 6 months prior to *** participants were randomly assigned with 1:1 to receive a booster dose of NVSI-06-09 or *** primary outcomes were immunogenicity and safety against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron variant,and the exploratory outcome was cross-immunogenicity against other circulating *** May 25 and 30,2022,516 adults received booster vaccination with 260 in NVSI-06-09 group and 256 in BBIBP-CorV *** results showed a similar safety profile between two booster groups,with low incidence of adverse reactions of grade 1 or *** immunogenicity,by day 14 post-booster,the fold rises in neutralizing antibody geometric mean titers(GMTs)from baseline elicited by NVSI-06-09 were remarkably higher than those by BBIBP-CorV against the prototype strain(19.67 vs 4.47-fold),Omicron BA.1.1(42.35 vs 3.78-fold),BA.2(25.09 vs 2.91-fold),BA.4(22.42 vs 2.69-fold),and BA.5 variants(27.06 vs 4.73-fold).Similarly,the neutralizing GMTs boosted by NVSI-06-09 against Beta and Delta variants were also 6.60-fold and 7.17-fold higher than those by *** findings indicated that a booster dose of NVSI-06-09 was well-tolerated and elicited broad-spectrum neutralizing responses against divergent SARS-CoV-2 variants,including Omicron and its sub-lineages.

关键词： phase neutral spectrum